Principal Financial Group Inc Arbutus Biopharma Corp Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$3.12 - $4.56 $38,538 - $56,325	-12,352 Reduced 47.31%	13,755 $52,000
Q2 2024 Jul 29, 2024	SELL	$2.52 - $3.63 $38,659 - $55,687	-15,341 Reduced 37.01%	26,107 $80,000
Q1 2024 Apr 29, 2024	SELL	$2.26 - $2.92 $9,327 - $12,050	-4,127 Reduced 9.06%	41,448 $106,000
Q4 2023 Feb 07, 2024	SELL	$1.69 - $2.54 $42 - $63	-25 Reduced 0.05%	45,575 $113,000
Q3 2023 Nov 02, 2023	BUY	$1.9 - $2.27 $7,438 - $8,887	3,915 Added 9.39%	45,600 $92,000
Q2 2023 Aug 07, 2023	BUY	$2.24 - $3.06 $5,830 - $7,965	2,603 Added 6.66%	41,685 $95,000
Q1 2023 May 09, 2023	BUY	$2.23 - $3.1 $559 - $778	251 Added 0.65%	39,082 $118,000
Q4 2022 Feb 09, 2023	BUY	$1.91 - $2.85 $47,368 - $70,680	24,800 Added 176.75%	38,831 $90,000
Q3 2022 Nov 09, 2022	BUY	$1.88 - $2.88 $4,119 - $6,310	2,191 Added 18.51%	14,031 $27,000
Q2 2022 Aug 10, 2022	BUY	$1.98 - $3.17 $23,443 - $37,532	11,840 New	11,840 $32,000

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $490M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.